
Light Source News
12K posts

Light Source News
@LightSourceNews
Jesus is returning soon! Get saved! If you've been diagnosed with cancer, go here! https://t.co/8FtDmqqDL5


THE UNBORN BABIES USED FOR DEVELOPMENT WERE ALIVE AT TISSUE EXTRACTION 😳 "The babies are still alive when the researchers start extracting the tissue; to the point where their heart is still beating, and they're generally not given any anesthetic, because that would disrupt the cells that the researchers are trying to extract." • PAMELA ACKER, BIOLOGIST According to Dr. Theresa Deisher babies are born alive from five to six months old, with beating hearts cut out without anesthesia for research purposes; researchers also cut through live babies' faces to collect brain tissue. DR. THERESA DEISHER, PH.D. MOLECULAR AND CELLULAR PHYSIOLOGY DR. STANLEY PLOTKIN, DUBBED THE "GODFATHER OF VACCINES." UNDER-OATH DEPOSITION 2018 #Truth

Canada IS NOT a democracy. Explained in under three minutes with receipts 👇

Who votes for the Islamic Republic of Iran to shape policy on women's rights, human rights, disarmament, and terrorism prevention? Canada. At the UN. Today.

Wanna read something insane? Read this about my country sending cease and desist orders to doctors who bought their own MRI machines to provide better services. No wonder MAID will soon be the most requested medical service in Canada. Life here sucks!






New Access to Information Request Reveals Hundreds of Canadians Died After COVID-19 Vaccination, Majority Within Two Days or Less From Severe Reactions. A newly released file under the Access to Information Act provides a detailed breakdown of reports submitted to Canada’s national vaccine safety surveillance system involving deaths that occurred following COVID-19 vaccination. The 50-page release from the Public Health Agency of Canada (PHAC) contains individual level entries drawn from the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS), covering reports recorded between March 1, 2020, and February 12, 2026. CAEFISS operates as a federal, provincial, and territorial collaboration, combining both passive and active surveillance. Healthcare providers, public health authorities, and, in some cases, patients family members contribute reports. The records list 314 cases in which an adverse event following immunization (AEFI) was reported with an outcome of death. Each entry includes the vaccine administered, reported symptoms, and the time between vaccination and onset of symptoms. It is important to note that fewer than 10 percent of vaccine-related adverse events are reported to health authorities, meaning that tens of thousands of cases were likely never documented. In addition, it has become widely known that many doctors feared reprisal if they reported vaccine injuries, which would further distort the true numbers. The vaccines referenced in the access to information file include those manufactured by Pfizer-BioNTech (Comirnaty), Moderna (Spikevax), AstraZeneca (Vaxzevria), and others authorized during the pandemic. Reported symptoms vary widely and include cardiac events such as myocardial infarction and cardiac arrest, neurological events such as stroke and seizures, and other conditions including respiratory failure, thrombosis, and multi-organ complications. According to the file, time to onset of reaction ranged from less than a day to several weeks or, in some cases, was listed as unknown. However, the majority of deaths were reported within two days or less. A link to the access to information file is in the comments section.




🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️ We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology. This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate). Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day. The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery. At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]): ✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%) ✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%) ✅ 36.1% reported stable disease (95% CI: 28.1–44.9%) Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months. The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events. Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach. Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies. Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary. This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes. The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.” @twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson












